Using MRI to target radiation treatment in prostate cancer

A Prospective Study of Lower Dose Radiation (LO-RADS) for Prostate Cancer Using MRI Dose Mapping to Preserve Quality of Life

This study is testing if using MRI can help target radiation treatment more precisely for men with prostate cancer, aiming to reduce damage to healthy tissue while hitting cancer spots harder.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 60 (estimated)
• Ages: 18 Years and up
• Sex: Male
• Sponsor: University of Chicago (other)
• Drugs / interventions: chemotherapy, radiation
• Locations: 1 site (Chicago, Illinois)
• Trial ID: NCT06171269 on ClinicalTrials.gov

What this trial studies

This research aims to evaluate the safety and effectiveness of utilizing magnetic resonance imaging (MRI) to optimize radiation therapy for men with prostate cancer. The approach involves decreasing radiation doses to healthy areas of the prostate while intensifying doses to cancerous nodules. By mapping the prostate using MRI, the study seeks to enhance treatment precision and potentially improve patient outcomes. The trial will include adult males with confirmed prostate adenocarcinoma who meet specific eligibility criteria.

Who should consider this trial

Good fit: Ideal candidates are adult males aged 18 and older with intermediate- or high-risk prostate adenocarcinoma that is visible on MRI.

Not a fit: Patients with distant metastases or those who have previously undergone active treatment for prostate cancer may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could lead to more effective radiation treatments with fewer side effects for prostate cancer patients.

How similar studies have performed: Other studies have shown promise in using imaging techniques to tailor radiation therapy, suggesting this approach could be beneficial.

Eligibility criteria

Inclusion Criteria:

* Adult (≥ 18 years old) male patients with an ECOG Performance Status 0-2
* Histologically-confirmed, MRI-visible prostate adenocarcinoma with NCCN intermediate- or high-risk disease1 without extra-pelvic metastasis.

Exclusion Criteria:

* Distant metastases
* Prior active treatment for prostate cancer including radical prostatectomy, high-intensity focused ultrasound (HIFU), cryosurgery, ADT, or cytotoxic chemotherapy for treatment of prostate cancer. Patients with prostate cancer on active surveillance prior to the study are not excluded if they have not received active treatment.
* Prior pelvic radiotherapy including brachytherapy.
* Additional active concurrent malignancies (except localized cutaneous squamous or basal cell carcinomas).
* Comorbid conditions that, in the opinion of the treating radiation oncologist, preclude the patient from safely receiving the protocol-specified treatment including RT and/or ADT.
* Patients with contraindications to MRI including patients with ferromagnetic materials in their body (e.g. bioimplants, surgical hardware, shrapnel), patients who are unable to receive contrast due to history of allergy or impaired renal function (glomerular filtration rate \< 30 mil/min), and patients unable to tolerate MRI for other reasons (e.g. significant claustrophobia).
* Patients for whom hydrogel or hyaluronic acid spacer will be placed.
* Patients incapable of giving informed consent.
* Patients who are unable to adhere to the experimental protocols for any reason.

Where this trial is running

Chicago, Illinois

• University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois, United States (RECRUITING)

Study contacts

• Principal investigator: Stanley Liauw — University of Chicago
• Study coordinator: Clinical Trials Intake

Conditions: Prostate Cancer